AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$BSX

Mahoney Michael F purchased $9.0M of BSX

Mahoney Michael F (Chairman, President & CEO) purchased 186,240 shares of BOSTON SCIENTIFIC CORP (BSX) at $48.33 ($9.00M total) on 2026-08-03.

Original reporting
SEC EDGAR · Mahoney Michael F
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BSX
Bullish
medium confidence
Mentioned
$BSX
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BSXBullishLow
01

Why it matters

The newest fact is the CEO’s open-market purchase of 186,240 shares at $48.3323 on 2026-08-03, filed on 2026-08-05.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not introduce new fundamentals in the provided text.

03

What to watch

The article provides no context on prior insider activity, option exercises, or whether the CEO’s holdings are already large, limiting inference from the $9.0M figure.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Boston Scientific (BSX).

Company-level read

Ticker impact

$BSXBullishMedium confidence
Context

Boston Scientific CEO Michael F Mahoney bought 186,240 shares in an open-market Form 4 transaction worth about $9.0M.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a primary-source Form 4 and the buy size is notable, but there is no accompanying guidance, deal, or operational update in the text.

Market effects

Sector

No sector-wide implications are disclosed; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be driven by diversification, liquidity needs, or routine planned activity; the filing notes no 10b5-1 plan but does not prove conviction.

Key entities

  • issuer
    Boston Scientific

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Michael F Mahoney

    Chairman, President and CEO who purchased shares.

Read at source← All news

Related articles

AUG 5
$BSXMedAI 8/10

Boston Scientific’s Q2 Earnings Call: Our Top 5 Analyst Questions

Boston Scientific (BSX) reported Q2 revenue of $5.44B vs $5.36B estimates and adjusted EPS of $0.86 vs $0.83. Management said Interventional Cardiology, Endoscopy and Neuromodulation grew, while Electrophysiology and WATCHMAN slowed. CEO Michael Mahoney cited U.S. WATCHMAN market changes and competition, leading to lower Q3 revenue guidance and reduced full-year adjusted EPS midpoint to $3.30.

financialcontent.com6 min
JUL 31
$VTRSMed

Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

rttnews.com7 min
JUL 31
$BSXMedAI 8/10

FDA Issues an Early Alert on Boston Scientific Carotid Catheters After Reports of Tips Breaking Off

A device designed to prevent stroke during carotid artery procedures is being pulled from hospital shelves because its tip can break off inside an artery, where it may cause the exact injury the device exists to prevent. The FDA issued an early alert on July 24 about two Boston Scientific products: the ENROUTE Transcarotid Neuroprotection System and the ENROUTE Transcarotid Neuroprotection System Plus.

medicaldaily.com7 min
JUL 31
$BSXHighAI 9/10

Boston Scientific Q2 2026 earnings: profit forecast cut on Watchman slowdown

Boston Scientific posted second-quarter net sales of $5.44 billion and adjusted earnings of $0.86 per share on Wednesday, beating its own guidance, but the company trimmed its full-year profit outlook as demand for its Watchman heart implant fell short of expectations. The company now expects full-year 2026 adjusted earnings per share of $3.28 to $3.32, the company said. That compares to a prior forecast of $3.34 to $3.41 per share.

yahoo.com4 min
JUL 31
$BSXMedAI 8/10

Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares

Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.86 per share for the quarter, ahead of analysts' consensus estimate of $0.83.

yahoo.com4 min